Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 4/20 | 0.43 |
| ▸ | CSNK2B | P67870 | 4/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 4/20 | 0.43 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 10/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.42 |
| ▸ | MEN1 | O00255 | 5/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | CASP1 | P29466 | 3/20 | 0.42 |
| ▸ | CASP7 | P55210 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 7/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | ERN1 | O75460 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL926584 | 0.84 | PPARG (0.41) | RCE1MAPTKDM4ECYP3A4MEN1 | |
| SCHEMBL928112 | 0.77 | RCE1 (0.45) | CSNK2A2CSNK2BCSNK2A1RCE1MAPT | |
| SCHEMBL926217 | 0.74 | CSNK2A2 (0.47) | CSNK2A2CSNK2BCSNK2A1RCE1MAPT | |
| SCHEMBL4650608 | 0.64 | CSNK2A2 (0.82) | CSNK2A2CSNK2BCSNK2A1MAPTKDM4E | |
| SCHEMBL926583 | 0.63 | KMT2A (0.45) | RCE1MAPTKDM4EMEN1KMT2A | |
| SCHEMBL5043660 | 0.63 | CSNK2A2 (0.75) | CSNK2A2CSNK2BCSNK2A1MAPTKDM4E | |
| SCHEMBL7124716 | 0.62 | CSNK2A2 (0.74) | CSNK2A2CSNK2BCSNK2A1MAPTKDM4E | |
| SCHEMBL7076972 | 0.62 | KDM4E (0.69) | CSNK2A2CSNK2BCSNK2A1MAPTKDM4E | |
| SCHEMBL30714874 | 0.62 | ACHE (0.62) | CSNK2A2CSNK2BCSNK2A1MAPTKDM4E | |
| SCHEMBL7644201 | 0.62 | MAPT (0.46) | CSNK2A2CSNK2BCSNK2A1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372866-B2 | 2-aryl and 2-heteroaryl 4H-1-benzopyran-4-one-6-amidino derivatives, new pharmacological agents for the treatment of arthritis, cancer and related pain | ROTTAPHARM S.P.A. (IT) | 2013-02-12 | — | — | US | disclosed |
| EP-2268628-B1 | 2-ARYL AND 2 -HETEROARYL 4H-1-BENZOPYRAN-4-ONE-6-AMIDINO DERIVATIVES FOR THE TREATMENT OF ARTHRITIS, CANCER AND RELATED PAIN | ROTTAPHARM SPA (IT) | 2012-05-16 | — | — | EP | disclosed |
| US-20110003861-A1 | 2-ARYL AND 2-HETEROARYL 4H-1-BENZOPYRAN-4-ONE-6-AMIDINO DERIVATIVES, NEW PHARMACOLOGICAL AGENTS FOR THE TREATMENT OF ARTHRITIS, CANCER AND RELATED PAIN | ROTTAPHARM S.P.A. (IT) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003861-A1 | 2-ARYL AND 2-HETEROARYL 4H-1-BENZOPYRAN-4-ONE-6-AMIDINO DERIVATIVES, NEW PHARMACOLOGICAL AGENTS FOR THE TREATMENT OF ARTHRITIS, CANCER AND RELATED PAIN | NAT1, AADAC, OPRL1 | CSNK2A2 1153/4885CSNK2B 2039/4885CSNK2A1 1319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.